Targeting mTOR to overcome resistance to hormone and CDK4/6 inhibitors in ER-positive breast cancer models

Resistance to therapy remains a major obstacle in cancer management. Although treatment with hormone and CDK4/6 inhibitors is successful in luminal breast cancer, resistance to these treatments is frequent, highlighting the need for novel therapeutic strategies to delay disease progression and impro...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodriguez, María Jimena, Perrone, María Cecilia, Riggio, Marina, Palafox, Marta, Salinas, Valeria, Elia, Andrés, Salgueiro, Natali Daiana, Werbach, Andrea Eugenia, Marks, María Paula, Kauffman, Marcelo A., Vellón, Luciano, Serra, Violeta, Novaro, Virginia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9932145/
https://www.ncbi.nlm.nih.gov/pubmed/36792625
http://dx.doi.org/10.1038/s41598-023-29425-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9932145/
https://www.ncbi.nlm.nih.gov/pubmed/36792625
http://dx.doi.org/10.1038/s41598-023-29425-y

Ejemplares similares